Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Mustang Bio Inc

Company price
0.3541 USD -0.02 ( 4.30%)
Last update at 2026-11-20T21:00:00Z
VOLUME
24670
Market Cap
2.36M

Momentum Score

…

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.35
Low
0.38
High
52 Week Price Range
0.16
Low
8.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Mustang Bio is a clinical-stage company developing cell and gene therapies for oncology and rare genetic diseases through R&D, clinical trials and manufacturing. Long-term growth drivers include clinical progress, strategic collaborations and manufacturing scale, which may attract investors seeking exposure to high‑unmet‑need cell and gene therapy programs.
Key risks are clinical or regulatory setbacks, substantial cash burn and financing needs, manufacturing complexity, and competition from better‑funded companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.37
Dividend Yield
-
Revenue TTM
-0.05M
Revenue Per Share
-0.00
Gross Profit TTM
0.00M
Debt / Equity
20.31
ROE
-322.45%
Net Debt
-3.74M
ROCE
-3212.10%
Diluted EPS TTM
-4.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -77.53M -66.37M -60.02M -46.39M -30.66M
Net income -78.89M -64.08M -62.15M -48.16M -30.66M
Selling general administrative 12.21M 11.02M 9.51M 9.57M 6.76M
Gross profit - - - - 0.00M
Reconciled depreciation 3.03M 2.31M 1.78M 1.37M 0.63M
Ebit -76.16M -66.72M -56.81M -45.88M -30.65M
Ebitda -74.17M -66.36M -56.10M -43.25M -30.02M
Depreciation and amortization 1.99M 0.37M 0.71M 2.63M 0.63M
Non operating income net other - - 0.71M 1.26M 0.57M
Operating income -76.16M -66.72M -56.81M -45.88M -31.22M
Other operating expenses 74.86M 66.72M 56.81M 45.88M 31.22M
Interest expense 3.36M 0.01M 3.92M 1.77M 0.01M
Interest income 0.69M 0.37M 0.71M 1.26M 0.57M
Net interest income -2.67M 0.35M -3.21M -0.50M 0.56M
Non recurring - - 10.06M 6.27M 3.36M
Income tax expense 1.37M -2.29M 2.13M 1.77M 0.57M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 74.86M 66.72M 56.81M 45.88M 31.22M
Cost of revenue - - - - 0.00M
Total other income expense net -1.37M 0.35M -3.21M -0.50M 0.56M
Net income from continuing ops -77.53M -66.37M -60.02M -46.39M -30.66M
Net income applicable to common shares -77.53M -66.37M -60.02M -46.39M -30.66M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 17.74M 92.42M 125.17M 109.90M 73.44M
Other current assets 1.23M 3.16M 2.04M 1.72M 1.63M
Total liab 17.62M 46.15M 12.77M 11.46M 21.79M
Total stockholder equity 0.12M 46.27M 112.40M 98.44M 51.65M
Other current liab 8.26M -0.27M -0.27M 9.24M 3.79M
Common stock 0.00M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.00M 0.01M 0.01M 0.01M 0.00M
Retained earnings -380.97M -329.37M -251.84M -185.47M -125.46M
Other liab - 0.27M 0.27M - -
Other assets - - 1.36M 2.84M 1.25M
Cash 6.23M 75.66M 109.62M 97.80M 61.41M
Total current liabilities 15.37M 15.11M 10.81M 9.52M 7.77M
Current deferred revenue 0.27M 0.27M 0.27M -9.24M -
Net debt -3.74M -44.27M -107.58M -95.58M -45.88M
Short term debt 0.52M 0.61M 0.35M 0.28M 1.51M
Short long term debt - - - - 1.25M
Short long term debt total 2.50M 31.38M 2.03M 2.23M 15.53M
Other stockholder equity 380.50M 375.63M 364.24M 283.90M 177.11M
Property plant equipment - 12.31M 12.10M 9.12M 9.13M
Total current assets 11.35M 78.85M 111.71M 99.53M 63.06M
Net tangible assets - - 112.40M 98.44M 51.65M
Short term investments - - - - 0.00M
Net receivables 3.88M 0.04M 0.05M 0.01M 0.02M
Long term debt - 27.44M - - 12.18M
Accounts payable 6.32M 14.50M 10.47M 9.24M 2.47M
Accumulated other comprehensive income 0.59M - - - -1.89M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -185.47M -125.46M
Non currrent assets other 0.83M 1.26M 1.36M 1.25M 1.25M
Non current assets total 6.40M 13.57M 13.46M 10.37M 10.38M
Capital lease obligations 2.50M 3.95M 2.03M 2.23M 2.10M
Long term debt total - - - - 12.18M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.95M -5.37M -4.41M 17.60M 8.50M
Change to liabilities - -0.14M 3.15M 0.36M 2.57M
Total cashflows from investing activities - -5.37M -4.41M 13.91M 0.56M
Net borrowings - - -15.75M -1.39M 15.00M
Total cash from financing activities 34.06M 70.85M 78.12M 65.12M 0.18M
Change to operating activities - -0.46M -0.06M -0.14M -0.00M
Net income -77.53M -66.37M -60.02M -46.39M -30.66M
Change in cash -33.96M 11.81M 36.39M 45.44M -18.51M
Begin period cash flow 110.62M 98.80M 62.41M 16.97M 35.48M
End period cash flow 76.66M 110.62M 98.80M 62.41M 16.97M
Total cash from operating activities -65.07M -53.67M -37.32M -33.58M -19.24M
Issuance of capital stock 6.62M 71.92M 97.03M 54.14M 0.00M
Depreciation 3.03M 2.31M 1.78M 1.37M 0.63M
Other cashflows from investing activities - - -2.49M -1.35M -1.07M
Change to account receivables - -0.04M 0.00M -0.02M -0.02M
Sale purchase of stock - - 35.19M 29.54M 0.18M
Other cashflows from financing activities 27.43M -1.07M -3.16M 10.98M 0.18M
Change to netincome - 11.03M 15.50M 2.66M 4.96M
Capital expenditures 3.08M 5.37M 4.41M 3.69M 7.95M
Change receivables - - 0.00M -0.02M -0.04M
Cash flows other operating - - 15.81M 7.83M 3.29M
Cash and cash equivalents changes - - 36.39M 45.44M -18.51M
Change in working capital 4.03M -0.64M 3.09M 0.13M 2.47M
Stock based compensation 2.28M 3.31M 2.99M 2.66M 4.96M
Other non cash items 3.12M 7.73M 14.83M 8.64M 3.36M
Free cash flow -68.14M -59.03M -41.73M -37.28M -27.19M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MBIO
Mustang Bio Inc
-0.02
4.30%
0.35 - - - 42.91 -0.03
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Mustang Bio Inc

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

377 Plantation Street, Worcester, MA, United States, 01605

781 652 4500

80

Name Title Year Born
Mr. Michael S. Weiss Esq. Exec. Chairman 1966
Dr. Manuel Litchman M.D. Pres, CEO & Director 1954
Mr. Eliot M. Lurier CPA Interim Chief Financial Officer 1958
Dr. Knut Niss Chief Technology Officer NA
Mr. Matthew Wein J.D. VP & Gen. Counsel NA
Ms. Debra Manning SPHR Sr. VP of HR NA
Mr. Scott Smith M.B.A. Exec. Director and Head of Alliance & Program Management NA
Dr. Bruce Dezube M.D. Sr. VP & Head of Clinical Devel. NA
Mr. Greg Furrow M.S. Sr. VP of Quality NA
Ms. Robyn M. Hunter Corp. Sec. 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…